ProMIS Neurosciences, Inc. (PMN) 株式分析

企業概要

ProMIS Neurosciences, Inc. is an enterprise engaged in the discovery and development of antibody therapies and therapeutic vaccines specifically targeting neurodegenerative diseases and other conditions caused by misfolded proteins within the Canadian market. The company operates within the Healthcare sector and the Biotechnology industry, a classification that denotes a focus on high-risk, high-reward research and development activities aimed at creating novel biological treatments. In terms of scale, the firm holds a market capitalization of 132.18 米ドル、but reports no annual revenue figures as listed in the available data, and the employee count is not disclosed. These financial metrics indicate that the company is a micro-cap entity operating with a significant valuation relative to its current financial output, suggesting that its market price is heavily influenced by future potential rather than established earnings history or current revenue generation.

財務健全性

The company reports a Net Income (TTM) of -39,719,148 米ドル、while Revenue (TTM) and EBITDA are listed as N/A, indicating that the firm is not yet generating profitable operations or consistent cash earnings. Although specific revenue figures are unavailable to calculate the gap directly, the substantial negative net income reveals a cost structure where research and development expenditures significantly exceed any current income streams. Free Cash Flow is listed as N/A, which implies that the company does not currently generate sufficient operating cash to fund its operations without relying entirely on external capital markets or existing reserves. Regarding liquidity, the company maintains cash reserves of 6.15 米ドル、while holding zero in debt, creating a unique financial profile for a biotechnology firm. The balance sheet is neither conservative nor leveraged in the traditional sense due to the absence of debt, but rather reflects a capital-intensive structure typical of pre-revenue stage biotech entities. The Current Ratio stands at 0.88, indicating that the company's current assets are slightly lower than its current liabilities, which suggests a potential strain on short-term liquidity that must be managed through future financing or milestone achievements. Return on Equity is -521.6% and Return on Assets is -178.7%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common characteristic in the early phases of biotechnology development before product approval.

バリュエーション評価

The P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -24.16, a figure that implies the market is pricing in future earnings expectations that are not yet realized in the trailing twelve months. The Price to Book ratio is -25.20, which indicates that the market value of the stock is significantly below its book value, a situation often seen in distressed or pre-profitability biotechnology stocks where asset valuations may include goodwill or intangible R&D costs not reflected on the balance sheet. Price to Sales and EV/EBITDA are both N/A, meaning traditional multiple-based valuation methods cannot be applied, suggesting investors must rely on alternative metrics or pipeline potential to assess value. The stock's 52-Week High is 39.75 米ドル、and the 52-Week Low is 6.27 米ドル、providing a trading range of 33.48 米ドル within which the current price fluctuates. The Beta is -0.40, a negative value that suggests the stock's price movements are inversely correlated with the broader market, exhibiting volatility that moves counter to general market trends rather than with them.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue due to the lack of historical revenue data in the provided facts. Since the company has no dividend yield (N/A) and a Payout Ratio of 0.0%, it does not distribute profits to shareholders, which is consistent with its status as a non-dividend payer that must reinvest any available capital or raise new funds to sustain operations. The absence of a dividend yield confirms that the company reinvests all available resources, including its cash reserves of 6.15 米ドル、into its proprietary discovery platform and the development of its antibody therapies and therapeutic vaccines. Overall, the growth and income profile of ProMIS Neurosciences, Inc. is characterized by a total reliance on capital raising and operational efficiency to fund growth, as indicated by the negative financial returns and lack of dividend distribution mechanisms.